{"count": 13, "results": [{"_id": "36180593", "pmid": 36180593, "title": "Correction: Metformin prevents vascular damage in hypertension through the AMPK/ER stress pathway.", "journal": "Hypertens Res", "authors": ["Chen C", "Kassan A", "Castañeda D", "Gabani M", "Choi SK", "Kassan M"], "date": "2022-12-01T00:00:00Z", "doi": "10.1038/s41440-022-01027-7", "meta_date_publication": "2022 Dec", "meta_volume": "45", "meta_issue": "12", "meta_pages": "2031", "score": 50262.74, "text_hl": "Correction: @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ prevents @<m>DISEASE_Vascular_System_Injuries</m> @DISEASE_MESH:D057772 @@@vascular damage@@@ in @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertension@@@ through the @GENE_PRKAA2 @GENE_5563 @@@AMPK@@@/ER stress pathway.", "citations": {"NLM": "Chen C, Kassan A, Castañeda D, Gabani M, Choi SK, Kassan M. Correction: Metformin prevents vascular damage in hypertension through the AMPK/ER stress pathway. Hypertens Res. 2022 Dec;45(12):2031. PMID: 36180593", "BibTeX": "@article{36180593, title={Correction: Metformin prevents vascular damage in hypertension through the AMPK/ER stress pathway.}, author={Chen C and Kassan A and Castañeda D and Gabani M and Choi SK and Kassan M}, journal={Hypertens Res}, volume={45}, number={12}, pages={2031}}"}}, {"_id": "34790753", "pmid": 34790753, "pmcid": "PMC8576656", "title": "Metformin alleviates bevacizumab-induced vascular endothelial injury by up-regulating GDF15 and activating the PI3K/AKT/FOXO/PPARgamma signaling pathway", "journal": "Ann Transl Med", "authors": ["Chen L", "Yin Y", "Liu G"], "date": "2021-10-01T00:00:00Z", "doi": "10.21037/atm-21-4764", "meta_date_publication": "2021 Oct", "meta_volume": "9", "meta_issue": "20", "meta_pages": "1547", "score": 50255.35, "text_hl": "Nonetheless, the effect of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in alleviating @CHEMICAL_Bevacizumab @CHEMICAL_MESH:D000068258 @@@bevacizumab@@@-induced @<m>DISEASE_Vascular_System_Injuries</m> @DISEASE_MESH:D057772 @@@vascular injury@@@ remains unknown. ", "citations": {"NLM": "Chen L, Yin Y, Liu G. Metformin alleviates bevacizumab-induced vascular endothelial injury by up-regulating GDF15 and activating the PI3K/AKT/FOXO/PPARgamma signaling pathway Ann Transl Med. 2021 Oct;9(20):1547. PMID: 34790753", "BibTeX": "@article{34790753, title={Metformin alleviates bevacizumab-induced vascular endothelial injury by up-regulating GDF15 and activating the PI3K/AKT/FOXO/PPARgamma signaling pathway}, author={Chen L and Yin Y and Liu G}, journal={Ann Transl Med}, volume={9}, number={20}, pages={1547}}"}}, {"_id": "40522519", "pmid": 40522519, "title": "Effect of Metformin on vascular endothelial injury in patients with non-small cell lung cancer treated with chemotherapy combined with bevacizumab.", "journal": "Cancer Chemother Pharmacol", "authors": ["Li H", "Pu Z", "Fang J"], "date": "2025-06-16T00:00:00Z", "doi": "10.1007/s00280-025-04780-x", "meta_date_publication": "2025 Jun 16", "meta_volume": "95", "meta_issue": "1", "meta_pages": "59", "score": 50253.47, "text_hl": "Effect of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ on @<m>DISEASE_Vascular_System_Injuries</m> @DISEASE_MESH:D057772 @@@vascular endothelial injury@@@ in @SPECIES_9606 @@@patients@@@ with @DISEASE_Carcinoma_Non_Small_Cell_Lung @DISEASE_MESH:D002289 @@@non-small cell lung cancer@@@ treated with chemotherapy combined with @CHEMICAL_Bevacizumab @CHEMICAL_MESH:D000068258 @@@bevacizumab@@@.", "citations": {"NLM": "Li H, Pu Z, Fang J. Effect of Metformin on vascular endothelial injury in patients with non-small cell lung cancer treated with chemotherapy combined with bevacizumab. Cancer Chemother Pharmacol. 2025 Jun 16;95(1):59. PMID: 40522519", "BibTeX": "@article{40522519, title={Effect of Metformin on vascular endothelial injury in patients with non-small cell lung cancer treated with chemotherapy combined with bevacizumab.}, author={Li H and Pu Z and Fang J}, journal={Cancer Chemother Pharmacol}, volume={95}, number={1}, pages={59}}"}}, {"_id": "34271418", "pmid": 34271418, "title": "Metformin inhibits polyphosphate-induced hyper-permeability and inflammation.", "journal": "Int Immunopharmacol", "authors": ["Asgharzadeh F", "Barneh F", "Fakhraie M", "Adel Barkhordar SL", "Shabani M", "Soleimani A", "Rahmani F", "Ariakia F", "Mehraban S", "Avan A", "Hashemzehi M", "Arjmand MH", "Behnam-Rassouli R", "Jaberi N", "Sayyed-Hosseinian SH", "Ferns GA", "Ryzhikov M", "Jafari M", "Khazaei M", "Hassanian SM"], "date": "2021-10-01T00:00:00Z", "doi": "10.1016/j.intimp.2021.107937", "meta_date_publication": "2021 Oct", "meta_volume": "99", "meta_issue": "", "meta_pages": "107937", "score": 50247.957, "text_hl": "These results support the clinical values of AMPK activators including the FDA-approved @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in attenuating @<m>DISEASE_Vascular_System_Injuries</m> @DISEASE_MESH:D057772 @@@vascular damage@@@ in @CHEMICAL_Polyphosphates @CHEMICAL_MESH:D011122 @@@polyP@@@-associated @DISEASE_Inflammation @DISEASE_MESH:D007249 @@@inflammatory diseases@@@.", "citations": {"NLM": "Asgharzadeh F, Barneh F, Fakhraie M, Adel Barkhordar SL, Shabani M, Soleimani A, Rahmani F, Ariakia F, Mehraban S, Avan A, Hashemzehi M, Arjmand MH, Behnam-Rassouli R, Jaberi N, Sayyed-Hosseinian SH, Ferns GA, Ryzhikov M, Jafari M, Khazaei M, Hassanian SM. Metformin inhibits polyphosphate-induced hyper-permeability and inflammation. Int Immunopharmacol. 2021 Oct;99():107937. PMID: 34271418", "BibTeX": "@article{34271418, title={Metformin inhibits polyphosphate-induced hyper-permeability and inflammation.}, author={Asgharzadeh F and Barneh F and Fakhraie M and Adel Barkhordar SL and Shabani M and Soleimani A and Rahmani F and Ariakia F and Mehraban S and Avan A and Hashemzehi M and Arjmand MH and Behnam-Rassouli R and Jaberi N and Sayyed-Hosseinian SH and Ferns GA and Ryzhikov M and Jafari M and Khazaei M and Hassanian SM}, journal={Int Immunopharmacol}, volume={99}, pages={107937}}"}}, {"_id": "33929389", "pmid": 33929389, "title": "Metformin Attenuates Hypoxia-induced Endothelial Cell Injury by Activating the AMP-Activated Protein Kinase Pathway.", "journal": "J Cardiovasc Pharmacol", "authors": ["Hu J", "Zheng Z", "Li X", "Li B", "Lai X", "Li N", "Lei S"], "date": "2021-06-01T00:00:00Z", "doi": "10.1097/FJC.0000000000001028", "meta_date_publication": "2021 Jun 1", "meta_volume": "77", "meta_issue": "6", "meta_pages": "862-874", "score": 50247.33, "text_hl": "However, results obtained after transfection with siPrkaa1 were in contrast to the results of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ treatment. In conclusion, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ can attenuate @<m>DISEASE_Vascular_System_Injuries</m> @DISEASE_MESH:D057772 @@@endothelial injuries@@@ and suppress EndMT of @CELLLINE_CVCL:D355 @@@HCMECs@@@ under @DISEASE_Hypoxia_Brain @DISEASE_MESH:D002534 @@@hypoxic@@@ conditions because of its ability to activate the @GENE_PRKAA1 @GENE_5562 @@@AMPK@@@ pathway, increase p-@GENE_PRKAA1 @GENE_5562 @@@AMPK@@@/AMP-activated protein kinase, and inhibit @GENE_MTOR @GENE_2475 @@@mammalian target of rapamycin@@@.", "citations": {"NLM": "Hu J, Zheng Z, Li X, Li B, Lai X, Li N, Lei S. Metformin Attenuates Hypoxia-induced Endothelial Cell Injury by Activating the AMP-Activated Protein Kinase Pathway. J Cardiovasc Pharmacol. 2021 Jun 1;77(6):862-874. PMID: 33929389", "BibTeX": "@article{33929389, title={Metformin Attenuates Hypoxia-induced Endothelial Cell Injury by Activating the AMP-Activated Protein Kinase Pathway.}, author={Hu J and Zheng Z and Li X and Li B and Lai X and Li N and Lei S}, journal={J Cardiovasc Pharmacol}, volume={77}, number={6}, pages={862-874}}"}}, {"_id": "30664704", "pmid": 30664704, "title": "Metformin prevents vascular damage in hypertension through the AMPK/ER stress pathway.", "journal": "Hypertens Res", "authors": ["Chen C", "Kassan A", "Castañeda D", "Gabani M", "Choi SK", "Kassan M"], "date": "2019-07-01T00:00:00Z", "doi": "10.1038/s41440-019-0212-z", "meta_date_publication": "2019 Jul", "meta_volume": "42", "meta_issue": "7", "meta_pages": "960-969", "score": 50068.344, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ prevents @<m>DISEASE_Vascular_System_Injuries</m> @DISEASE_MESH:D057772 @@@vascular damage@@@ in @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertension@@@ through the AMPK/ER stress pathway.", "citations": {"NLM": "Chen C, Kassan A, Castañeda D, Gabani M, Choi SK, Kassan M. Metformin prevents vascular damage in hypertension through the AMPK/ER stress pathway. Hypertens Res. 2019 Jul;42(7):960-969. PMID: 30664704", "BibTeX": "@article{30664704, title={Metformin prevents vascular damage in hypertension through the AMPK/ER stress pathway.}, author={Chen C and Kassan A and Castañeda D and Gabani M and Choi SK and Kassan M}, journal={Hypertens Res}, volume={42}, number={7}, pages={960-969}}"}}, {"_id": "26138461", "pmid": 26138461, "title": "Metformin reduces hepatic resistance and portal pressure in cirrhotic rats.", "journal": "Am J Physiol Gastrointest Liver Physiol", "authors": ["Tripathi DM", "Erice E", "Lafoz E", "García-Calderó H", "Sarin SK", "Bosch J", "Gracia-Sancho J", "García-Pagán JC"], "date": "2015-09-01T00:00:00Z", "doi": "10.1152/ajpgi.00010.2015", "meta_date_publication": "2015 Sep 1", "meta_volume": "309", "meta_issue": "5", "meta_pages": "G301-9", "score": 50057.15, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ ameliorates @<m>DISEASE_Vascular_System_Injuries</m> @DISEASE_MESH:D057772 @@@vascular@@@ cells function in several @<m>DISEASE_Vascular_System_Injuries</m> @DISEASE_MESH:D057772 @@@vascular@@@ beds. ", "citations": {"NLM": "Tripathi DM, Erice E, Lafoz E, García-Calderó H, Sarin SK, Bosch J, Gracia-Sancho J, García-Pagán JC. Metformin reduces hepatic resistance and portal pressure in cirrhotic rats. Am J Physiol Gastrointest Liver Physiol. 2015 Sep 1;309(5):G301-9. PMID: 26138461", "BibTeX": "@article{26138461, title={Metformin reduces hepatic resistance and portal pressure in cirrhotic rats.}, author={Tripathi DM and Erice E and Lafoz E and García-Calderó H and Sarin SK and Bosch J and Gracia-Sancho J and García-Pagán JC}, journal={Am J Physiol Gastrointest Liver Physiol}, volume={309}, number={5}, pages={G301-9}}"}}, {"_id": "19488607", "pmid": 19488607, "pmcid": "PMC2694245", "title": "Short-Term Treatment with Metformin Improves the Cardiovascular Risk Profile in First-Degree Relatives of Subjects with Type 2 Diabetes Mellitus who have a Metabolic Syndrome and Normal Glucose Tolerance without Changes in C-Reactive Protein or Fibrinogen", "journal": "Clinics (Sao Paulo)", "authors": ["Lima LM", "Wiernsperger N", "Kraemer-Aguiar LG", "Bouskela E"], "date": "2009-05-01T00:00:00Z", "doi": "10.1590/s1807-59322009000500008", "meta_date_publication": "2009 May", "meta_volume": "64", "meta_issue": "5", "meta_pages": "415-20", "score": 50051.934, "text_hl": "@DISEASE_Metabolic_Syndrome @DISEASE_MESH:D024821 @@@Metabolic syndrome@@@ is associated with higher cardiovascular morbidity and mortality. @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ has vasculo-protective effects even in normoglycemic subjects, and @GENE_CRP @GENE_1401 @@@C-reactive protein@@@ and @GENE_FGB @GENE_2244 @@@fibrinogen@@@ are considered markers of @<m>DISEASE_Vascular_System_Injuries</m> @DISEASE_MESH:D057772 @@@endothelial injury@@@ and @DISEASE_Inflammation @DISEASE_MESH:D007249 @@@inflammation@@@.", "citations": {"NLM": "Lima LM, Wiernsperger N, Kraemer-Aguiar LG, Bouskela E. Short-Term Treatment with Metformin Improves the Cardiovascular Risk Profile in First-Degree Relatives of Subjects with Type 2 Diabetes Mellitus who have a Metabolic Syndrome and Normal Glucose Tolerance without Changes in C-Reactive Protein or Fibrinogen Clinics (Sao Paulo). 2009 May;64(5):415-20. PMID: 19488607", "BibTeX": "@article{19488607, title={Short-Term Treatment with Metformin Improves the Cardiovascular Risk Profile in First-Degree Relatives of Subjects with Type 2 Diabetes Mellitus who have a Metabolic Syndrome and Normal Glucose Tolerance without Changes in C-Reactive Protein or Fibrinogen}, author={Lima LM and Wiernsperger N and Kraemer-Aguiar LG and Bouskela E}, journal={Clinics (Sao Paulo)}, volume={64}, number={5}, pages={415-20}}"}}, {"_id": "15931622", "pmid": 15931622, "title": "Metformin decreases intracellular production of reactive oxygen species in aortic endothelial cells.", "journal": "Metabolism", "authors": ["Ouslimani N", "Peynet J", "Bonnefont-Rousselot D", "Thérond P", "Legrand A", "Beaudeux JL"], "date": "2005-06-01T00:00:00Z", "doi": "10.1016/j.metabol.2005.01.029", "meta_date_publication": "2005 Jun", "meta_volume": "54", "meta_issue": "6", "meta_pages": "829-34", "score": 50048.957, "text_hl": "Beyond its antidiabetic activity justifying its use in the treatment of the @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@type 2 diabetes@@@, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ (@CHEMICAL_Methionine @CHEMICAL_MESH:D008715 @@@MET@@@ [dimethylguanidine, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Glucophage@@@]) has been shown to exhibit antioxidant properties in vitro, which could contribute to limit the deleterious @<m>DISEASE_Vascular_System_Injuries</m> @DISEASE_MESH:D057772 @@@vascular@@@ complications of @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetes@@@. ", "citations": {"NLM": "Ouslimani N, Peynet J, Bonnefont-Rousselot D, Thérond P, Legrand A, Beaudeux JL. Metformin decreases intracellular production of reactive oxygen species in aortic endothelial cells. Metabolism. 2005 Jun;54(6):829-34. PMID: 15931622", "BibTeX": "@article{15931622, title={Metformin decreases intracellular production of reactive oxygen species in aortic endothelial cells.}, author={Ouslimani N and Peynet J and Bonnefont-Rousselot D and Thérond P and Legrand A and Beaudeux JL}, journal={Metabolism}, volume={54}, number={6}, pages={829-34}}"}}, {"_id": "27737949", "pmid": 27737949, "pmcid": "PMC5204316", "title": "Metformin Suppresses Diabetes-Accelerated Atherosclerosis via the Inhibition of Drp1-Mediated Mitochondrial Fission", "journal": "Diabetes", "authors": ["Wang Q", "Zhang M", "Torres G", "Wu S", "Ouyang C", "Xie Z", "Zou MH"], "date": "2017-01-01T00:00:00Z", "doi": "10.2337/db16-0915", "meta_date_publication": "2017 Jan", "meta_volume": "66", "meta_issue": "1", "meta_pages": "193-205", "score": 50044.75, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ treatments markedly reduced @DISEASE_Sleep_Deprivation @DISEASE_MESH:D012892 @@@mitochondrial fragmentation@@@, mitigated mitochondrial-derived @CHEMICAL_Superoxides @CHEMICAL_MESH:D013481 @@@superoxide@@@ release, improved endothelial-dependent vasodilation, inhibited @<m>DISEASE_Vascular_System_Injuries</m> @DISEASE_MESH:D057772 @@@vascular@@@ @DISEASE_Inflammation @DISEASE_MESH:D007249 @@@inflammation@@@, and suppressed @DISEASE_Atherosclerosis @DISEASE_MESH:D050197 @@@atherosclerotic lesions@@@ in @CHEMICAL_Streptozocin @CHEMICAL_MESH:D013311 @@@streptozotocin@@@ (@CHEMICAL_Streptozocin @CHEMICAL_MESH:D013311 @@@STZ@@@)-induced @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetic@@@ @GENE_APOE @GENE_348 @@@ApoE@@@-/- @SPECIES_10090 @@@mice@@@. ", "citations": {"NLM": "Wang Q, Zhang M, Torres G, Wu S, Ouyang C, Xie Z, Zou MH. Metformin Suppresses Diabetes-Accelerated Atherosclerosis via the Inhibition of Drp1-Mediated Mitochondrial Fission Diabetes. 2017 Jan;66(1):193-205. PMID: 27737949", "BibTeX": "@article{27737949, title={Metformin Suppresses Diabetes-Accelerated Atherosclerosis via the Inhibition of Drp1-Mediated Mitochondrial Fission}, author={Wang Q and Zhang M and Torres G and Wu S and Ouyang C and Xie Z and Zou MH}, journal={Diabetes}, volume={66}, number={1}, pages={193-205}}"}}]}